Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

Chiu, Chao-HuaChao-HuaChiuLin, Meng-ChihMeng-ChihLinWei, Yu-FengYu-FengWeiChang, Gee-ChenGee-ChenChangSu, Wu-ChouWu-ChouSuHsia, Te-ChunTe-ChunHsiaSu, JianJianSuWang, Anne Kuei-FangAnne Kuei-FangWangJen, Min-HuaMin-HuaJenPuri, TarunTarunPuriJIN-YUAN SHIH2023-09-042023-09-042023-0717762596https://scholars.lib.ntu.edu.tw/handle/123456789/634976In RELAY, a randomized, double-blind, phase III trial investigating the efficacy and safety of ramucirumab+erlotinib (RAM+ERL) or ERL+placebo (PBO) in patients with untreated, stage IV, epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), RAM+ERL demonstrated superior progression-free survival (PFS) versus PBO+ERL, with no new safety signals.enEfficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Studyjournal article10.1007/s11523-023-00975-5373294232-s2.0-85161996331https://api.elsevier.com/content/abstract/scopus_id/85161996331